298 related articles for article (PubMed ID: 33122816)
1. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
Borchert S; Suckrau PM; Walter RFH; Wessolly M; Mairinger E; Steinborn J; Hegedus B; Hager T; Herold T; Eberhardt WEE; Wohlschlaeger J; Aigner C; Bankfalvi A; Schmid KW; Mairinger FD
Sci Rep; 2020 Oct; 10(1):18677. PubMed ID: 33122816
[TBL] [Abstract][Full Text] [Related]
2. Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma.
Kaku Y; Nagaya H; Tsuchiya A; Kanno T; Gotoh A; Tanaka A; Shimizu T; Nakao S; Tabata C; Nakano T; Nishizaki T
Cancer Sci; 2014 Jul; 105(7):883-9. PubMed ID: 24754309
[TBL] [Abstract][Full Text] [Related]
3. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
Onen HI; Yilmaz A; Alp E; Celik A; Demiroz SM; Konac E; Kurul IC; Menevse ES
Hum Exp Toxicol; 2015 Feb; 34(2):117-26. PubMed ID: 25028262
[TBL] [Abstract][Full Text] [Related]
4. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M
Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945
[TBL] [Abstract][Full Text] [Related]
5. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
6. Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.
Riquelme E; Suraokar MB; Rodriguez J; Mino B; Lin HY; Rice DC; Tsao A; Wistuba II
J Thorac Oncol; 2014 Jul; 9(7):998-1007. PubMed ID: 24926545
[TBL] [Abstract][Full Text] [Related]
7. Cancer-Associated Fibroblasts Regulate Kinase Activity in Mesothelioma Cell Lines via Paracrine Signaling and Thereby Dictate Cell Faith and Behavior.
Mathilakathu A; Wessolly M; Mairinger E; Uebner H; Kreidt D; Brcic L; Steinborn J; Greimelmaier K; Wohlschlaeger J; Schmid KW; Mairinger FD; Borchert S
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328699
[TBL] [Abstract][Full Text] [Related]
8. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
9. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
Lam SK; Li YY; Xu S; Leung LL; U KP; Zheng YF; Cheng PN; Ho JC
Respir Res; 2017 May; 18(1):80. PubMed ID: 28464918
[TBL] [Abstract][Full Text] [Related]
10. Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy.
Borchert S; Suckrau PM; Wessolly M; Mairinger E; Hegedus B; Hager T; Herold T; Eberhardt WEE; Wohlschlaeger J; Aigner C; Bankfalvi A; Schmid KW; Walter RFH; Mairinger FD
J Oncol; 2019; 2019():2902985. PubMed ID: 31929796
[TBL] [Abstract][Full Text] [Related]
11. Induction of metallothionein expression by supplementation of zinc induces resistance against platinum-based treatment in malignant pleural mesothelioma.
Wyrich M; Ohlig H; Wessolly M; Mairinger E; Steinborn J; Brcic L; Hegedus B; Hager T; Greimelmaier K; Wohlschlaeger J; Mairinger FD; Borchert S
Transl Cancer Res; 2023 Aug; 12(8):1929-1936. PubMed ID: 37701096
[TBL] [Abstract][Full Text] [Related]
12. Alterations in
Oehl K; Vrugt B; Wagner U; Kirschner MB; Meerang M; Weder W; Felley-Bosco E; Wollscheid B; Bankov K; Demes MC; Opitz I; Wild PJ
Clin Cancer Res; 2021 Apr; 27(8):2277-2291. PubMed ID: 33547197
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
Di Marzo D; Forte IM; Indovina P; Di Gennaro E; Rizzo V; Giorgi F; Mattioli E; Iannuzzi CA; Budillon A; Giordano A; Pentimalli F
Cell Cycle; 2014; 13(4):652-65. PubMed ID: 24345738
[TBL] [Abstract][Full Text] [Related]
14. A comparison between the effects of over-expression of miRNA-16 and miRNA-34a on cell cycle progression of mesothelioma cell lines and on their cisplatin sensitivity.
Pinelli S; Alinovi R; Corradi M; Poli D; Cavallo D; Pelosi G; Ampollini L; Goldoni M; Mozzoni P
Cancer Treat Res Commun; 2021; 26():100276. PubMed ID: 33338854
[TBL] [Abstract][Full Text] [Related]
15. [Effects of microRNA-106b on migration and invasion of human malignant pleural mesothelioma cell NCI-H2452].
Gao YN; Zhang M; Zhang FF; Jia ZY; Yuan XY; Zhu LJ
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Sep; 41(9):648-654. PubMed ID: 37805422
[No Abstract] [Full Text] [Related]
16. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD
BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254
[TBL] [Abstract][Full Text] [Related]
17. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
[TBL] [Abstract][Full Text] [Related]
18. Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis.
Plönes T; Fischer M; Höhne K; Sato H; Müller-Quernheim J; Zissel G
Pathol Oncol Res; 2017 Oct; 23(4):723-730. PubMed ID: 28054314
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.
Varin E; Denoyelle C; Brotin E; Meryet-Figuière M; Giffard F; Abeilard E; Goux D; Gauduchon P; Icard P; Poulain L
Carcinogenesis; 2010 Jun; 31(6):984-93. PubMed ID: 20142415
[TBL] [Abstract][Full Text] [Related]
20. The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.
Oguh-Olayinka L; Agarwal V; Ranatunge D; Campbell A; Laufer S; Cawkwell L; Lind MJ
Pathol Oncol Res; 2020 Apr; 26(2):985-995. PubMed ID: 30941737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
